<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04640987</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-58549</org_study_id>
    <secondary_id>BMT 367 - T-allo10 Alpha Beta</secondary_id>
    <nct_id>NCT04640987</nct_id>
  </id_info>
  <brief_title>Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback</brief_title>
  <official_title>Phase 1/1b Study of T-allo10 Infusion After HLA-Partially Matched Related or Unrelated TCR αβ+ T-cell/ CD19+ B-cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (αβ Depleted-HSCT) in Children and Young Adults Affected by Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety of a cell therapy, T-allo10, after&#xD;
      αβdepleted-HSCT in the hopes that it will boost the adaptive immune reconstitution of the&#xD;
      patient while sparing the risk of developing severe Graft-versus-Host Disease (GvHD).&#xD;
&#xD;
      The primary objective of Phase 1 is to determine the recommended Phase 2 dose (RP2D)&#xD;
      administered after infusion of αβdepleted-HSCT in children and young adults with hematologic&#xD;
      malignancies.&#xD;
&#xD;
      A Phase 1b extension will occur after dose escalation, enrolling at the RP2D for the T-allo10&#xD;
      cells determined in the Phase 1 portion to evaluate the safety and efficacy of infusion of&#xD;
      T-allo10 after receipt of αβdepleted-HSCT. Additionally, Phase 1b aims to explore&#xD;
      improvements in immune reconstitution.&#xD;
&#xD;
      All participants on this study must be enrolled on another study: NCT04249830&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2020</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with myeloid engraftment after T-allo10</measure>
    <time_frame>Through day 35 (+/- 7 days) after αβdepleted-HSCT</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants without grade II aGvHD requiring steroids after T-allo10</measure>
    <time_frame>Through day 35 (+/- 7 days) after αβdepleted-HSCT</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants without grade III/IV aGvHD after T-allo10</measure>
    <time_frame>Through day 35 (+/- 7 days) after αβdepleted-HSCT</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with absence of dose-limiting toxicity (DLT) 28 days following the infusion of T-allo10 given at the recommended phase 2 dose (RP2D)</measure>
    <time_frame>Assessed at 28 days (after infusion of T-allo10)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who reach immune reconstitution (IR) threshold</measure>
    <time_frame>Through Day 60 (+/- 10 days) after infusion of T-allo10</time_frame>
    <description>IR (a surrogate of reduced risk of leukemia recurrence) is defined reaching the threshold of 50CD3+CD4+T-cells/µl by Day+60(+/-10days).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with ≥grade 3 adverse event related to T-allo10 infusion</measure>
    <time_frame>Through 1 year after αβdepleted-HSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with grade II-IV aGvHD</measure>
    <time_frame>Assessed at day 90 after αβdepleted-HSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with grade III-IV aGvHD</measure>
    <time_frame>Assessed at day 180 after αβdepleted-HSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with cGvHD</measure>
    <time_frame>Assessed at 1 year after αβdepleted-HSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukemia-free survival</measure>
    <time_frame>Assessed at 1 year after αβdepleted-HSCT</time_frame>
    <description>Leukemia-free survival defined as at the time of enrollment to disease relapse or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with disease relapse</measure>
    <time_frame>Assessed at 1 year after αβdepleted-HSCT</time_frame>
    <description>Disease relapse is defined as the return of signs and symptoms of a disease after a remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>Assessed at Day 90 after αβdepleted-HSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>Assessed at 1 year after αβdepleted-HSCT</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Hematologic Diseases</condition>
  <arm_group>
    <arm_group_label>Experimental: Stem Cell Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participant will undergo a stem cell transplant using donor cells that have been manipulated through an investigational device. The participant's cells will then be manipulated via a T-allo10 cell addback. Participants will be followed for outcomes for two years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic Stem Cell Transplant</intervention_name>
    <description>The allogeneic stem cell transplant involves transferring the stem cells from a healthy person (donor) to the participant via infusion.</description>
    <arm_group_label>Experimental: Stem Cell Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CliniMACS Prodigy System</intervention_name>
    <description>Device used for production of T-allo10 cells.</description>
    <arm_group_label>Experimental: Stem Cell Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T-allo10 cells addback</intervention_name>
    <description>T-allo10 cells are made by manipulating the participant's stem cell donor's white blood cells (CD4+ T cells) in the presence of their (participant's) CD14+ monocytes.</description>
    <arm_group_label>Experimental: Stem Cell Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria prior to enrollment:&#xD;
&#xD;
          -  1. Age &gt; 1 months (with minimum weight of 10 Kg) and &lt; 45 years.&#xD;
&#xD;
          -  2. Patients deemed eligible for allogeneic HSCT under the originating study, NCT&#xD;
             04249830&#xD;
&#xD;
          -  3. Patients with life-threatening hematological malignancies for which HSCT has been&#xD;
             recommended:&#xD;
&#xD;
               1. High-risk ALL in 1st CR, ALL in 2nd or subsequent CR;&#xD;
&#xD;
               2. High-risk AML in 1st CR, AML in 2nd or subsequent CR;&#xD;
&#xD;
               3. Myelodysplastic syndrome;&#xD;
&#xD;
               4. JMML (Juvenile myelomonocytic leukemia);&#xD;
&#xD;
               5. Non-Hodgkin lymphomas in 2nd or subsequent CR;&#xD;
&#xD;
               6. Other hematologic malignancies eligible for stem cell transplantation per&#xD;
                  institutional standard.&#xD;
&#xD;
          -  4. All subjects ≥ 18 years of age must be able to give informed consent, or adults&#xD;
             lacking capacity to consent must have a LAR available to provide consent. For subjects&#xD;
             &lt;18 years old their LAR (i.e. parent or guardian) must give informed consent.&#xD;
             Pediatric subjects will be included in age appropriate discussion and verbal assent&#xD;
             will be obtained for those &gt; 7 years of age, when appropriate.&#xD;
&#xD;
        Inclusion criteria prior to T-allo10 infusion:&#xD;
&#xD;
          1. Patient already received αβdepleted-HSCT and has myeloid engraftment.&#xD;
&#xD;
          2. Absence of active grade II aGvHD requiring &gt;0.5 mg/Kg of steroids or any diagnosis of&#xD;
             grade III/IVaGvHD.&#xD;
&#xD;
        Exclusion Criteria prior to MNC collection for Tallo-10 manufacturing.:&#xD;
&#xD;
          1. Not eligible to receive HSCT on NCT04249830&#xD;
&#xD;
          2. Received another investigational agent within 30 days of enrollment.&#xD;
&#xD;
          3. Pregnancy (positive serum or urine beta-HCG) within 7 days of MNC donation.&#xD;
&#xD;
          4. Patient or donor is not willing or able to undergo an additional non-mobilized&#xD;
             apheresis for collection of MNC prior to donation of cells for participation in&#xD;
             NCT04249830.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alice Bertaina, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor of Pediatrics, Stem Cell Transplantation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Pukesh</last_name>
      <phone>650-724-4622</phone>
      <email>scgt_clinical_trials_office@lists.stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Rosa Bacchetta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Shyr, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rajni Agarwal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 17, 2020</study_first_submitted>
  <study_first_submitted_qc>November 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2020</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Alice Bertaina</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

